Goal is to merge companies’ digital therapeutics and technology expertise
etectRx, Inc., a digital health company, has entered into an agreement with Pear Therapeutics, Inc., a prescription digital therapeutics (PDTs) provider.
The objective: develop up to two product candidates in the central nervous system (CNS) sector that combine PDTs and adherence sensors. The companies say that this partnership is the first to explore the use of digital pill solutions with PDTs.
etectRx’s ingestible sensor, the ID-Cap System
etectRx’s FDA-cleared ID-Cap System, a digital pill system that the company says is accurate and flexible, enhances adherence to oral medication and helps to improve patient outcomes. Specifically, FDA cleared ID-Cap System as an ingestible event marker, which has the ability to guide digital and non-digital therapeutic interventions. Once swallowed, its ID-Tag uses etectRx’s proprietary communications technology to transmit a very low power digital message from within the patient’s stomach.